Cure8 research brief
Remote text monitoring is appealing as a low-cost way to support people with IBD on biologics, but this trial suggests it may not boost quality of life or adherence over 4 months when adherence is already high. Patients and clinics should weigh feasibility and patient preference alongside expected benefit.
Adult patients with IBD receiving biologic therapy (home infusion or self-injection), clinicians managing outpatient IBD care, program planners considering remote monitoring, and researchers studying digital health interventions in IBD.
This was an individually randomized, 1:1 trial of adults receiving biologic therapy by home infusion or self-injection. The 4-month intervention sent dose reminders, asked adherence check-ins after doses, performed weekly symptom check-ins with escalation thresholds, and provided optional feedback to a support partner.
About the results: Among 150 enrolled participants (144 analyzed for survey outcomes), there were no significant differences between the remote monitoring and usual care arms for change in SIBDQ quality-of-life scores, MARS-5 adherence scores, patient satisfaction, or proportion of days covered for biologic dosing.
Medication adherence was high in both groups at baseline and during follow-up. Practical note: The study shows remote text-based monitoring can be implemented and accepted by patients but may not improve short-term quality-of-life or adherence when baseline adherence is already high.
This record is an abstract-level journal article reporting a completed randomized trial (clinicaltrials.gov NCT04388865). The intervention lasted 4 months and the cohort had high baseline adherence, which may limit the ability to show improvement. The content is based on the article abstract provided.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
